GenomicsAnnals of OncologyPeer-reviewed
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
Romualdo Barroso‐Sousa, Esha Jain, Ofir Cohen…·Nikhil Wagle
This study finds that 5% of breast cancers have high tumor mutation burden, more common in metastatic tumors, with APOBEC activity as the most common mutational process and potential benefit from PD-1 inhibitors.
363 citationstop 1%